Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 167

1.

CD4 cell count recovery after combined antiretroviral therapy in the modern cART era.

Roul H, Mary-Krause M, Ghosn J, Delaugerre C, Pialoux G, Cuzin L, Launay O, Lacombe JM, Menard A, De Truchis P, Delfraissy JF, Weiss L, Costagliola D; FHDH-ANRS CO4.

AIDS. 2018 Oct 4. doi: 10.1097/QAD.0000000000002010. [Epub ahead of print]

PMID:
30289817
2.

EBOLA : 2014-2015, une crise sanitaire majeure Pourquoi ? Quelles leçons ?

Delfraissy JF.

Sante Publique. 2017 Oct 2;29(4):447-450. doi: 10.3917/spub.174.0447. French. No abstract available.

PMID:
29034659
3.

Recurrent obstructive acute pyelonephritis: A rare form of Actinotignum (Actinobaculum) schaalii infection in a HIV-1 infected patient.

Vallet A, Noël N, Bahi R, Teicher E, Quertainmont Y, Delfraissy JF, Ferlicot S, Potron A, Goujard C, Lambotte O.

Anaerobe. 2017 Feb;43:75-77. doi: 10.1016/j.anaerobe.2016.12.004. Epub 2016 Dec 8.

PMID:
27940245
4.

Dyslipidemias and Elevated Cardiovascular Risk on Lopinavir-Based Antiretroviral Therapy in Cambodia.

Limsreng S, Marcy O, Ly S, Ouk V, Chanroeurn H, Thavary S, Boroath B, Canestri A, Viretto G, Delfraissy JF, Ségéral O.

PLoS One. 2016 Aug 31;11(8):e0160306. doi: 10.1371/journal.pone.0160306. eCollection 2016.

5.

Coordinating funding in public health emergencies.

Matthiessen L, Colli W, Delfraissy JF, Hwang ES, Mphahlele J, Ouellette M; GloPID-R members.

Lancet. 2016 May 28;387(10034):2197-8. doi: 10.1016/S0140-6736(16)30604-3. No abstract available.

PMID:
27302027
6.

State humanitarian verticalism versus universal health coverage: a century of French international health assistance revisited.

Atlani-Duault L, Dozon JP, Wilson A, Delfraissy JF, Moatti JP.

Lancet. 2016 May 28;387(10034):2250-62. doi: 10.1016/S0140-6736(16)00379-2. Epub 2016 May 1. Review.

PMID:
27145710
7.

REACTing: the French response to infectious disease crises.

Delfraissy JF, Yazdanpanah Y, Levy Y.

Lancet. 2016 May 28;387(10034):2183-5. doi: 10.1016/S0140-6736(16)30059-9. Epub 2016 May 1. No abstract available.

PMID:
27145708
8.

Cities central to HIV response for people who use drugs.

Tinasti K, Audoin B, Jomier B, Delfraissy JF, Lévy Y, Barré-Sinoussi F.

Lancet HIV. 2016 May;3(5):e197-9. doi: 10.1016/S2352-3018(16)30017-0. Epub 2016 Apr 11. No abstract available.

PMID:
27126484
9.

Public T cell receptors confer high-avidity CD4 responses to HIV controllers.

Benati D, Galperin M, Lambotte O, Gras S, Lim A, Mukhopadhyay M, Nouël A, Campbell KA, Lemercier B, Claireaux M, Hendou S, Lechat P, de Truchis P, Boufassa F, Rossjohn J, Delfraissy JF, Arenzana-Seisdedos F, Chakrabarti LA.

J Clin Invest. 2016 Jun 1;126(6):2093-108. doi: 10.1172/JCI83792. Epub 2016 Apr 25.

10.

Network for strong, national, public health institutes in west Africa.

Meda N, Dabis F, Desenclos JC, Crespin X, Delfraissy JF.

Lancet. 2016 May 28;387(10034):2196-7. doi: 10.1016/S0140-6736(16)30015-0. Epub 2016 Mar 21. No abstract available.

PMID:
27012763
11.

Repeated Cycles of Recombinant Human Interleukin 7 in HIV-Infected Patients With Low CD4 T-Cell Reconstitution on Antiretroviral Therapy: Results of 2 Phase II Multicenter Studies.

Thiébaut R, Jarne A, Routy JP, Sereti I, Fischl M, Ive P, Speck RF, D'Offizi G, Casari S, Commenges D, Foulkes S, Natarajan V, Croughs T, Delfraissy JF, Tambussi G, Levy Y, Lederman MM.

Clin Infect Dis. 2016 May 1;62(9):1178-1185. doi: 10.1093/cid/ciw065. Epub 2016 Feb 7.

12.

Adenosine deaminase is a useful biomarker to diagnose pleural tuberculosis in low to medium prevalence settings.

Michot JM, Madec Y, Bulifon S, Thorette-Tcherniak C, Fortineau N, Noël N, Lambotte O, El Jahiri Y, Delacour H, Delfraissy JF, Blanc FX.

Diagn Microbiol Infect Dis. 2016 Mar;84(3):215-20. doi: 10.1016/j.diagmicrobio.2015.11.007. Epub 2015 Nov 10.

PMID:
26707067
13.

On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.

Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, Tremblay C, Le Gall JM, Cua E, Pasquet A, Raffi F, Pintado C, Chidiac C, Chas J, Charbonneau P, Delaugerre C, Suzan-Monti M, Loze B, Fonsart J, Peytavin G, Cheret A, Timsit J, Girard G, Lorente N, Préau M, Rooney JF, Wainberg MA, Thompson D, Rozenbaum W, Doré V, Marchand L, Simon MC, Etien N, Aboulker JP, Meyer L, Delfraissy JF; ANRS IPERGAY Study Group.

N Engl J Med. 2015 Dec 3;373(23):2237-46. doi: 10.1056/NEJMoa1506273. Epub 2015 Dec 1.

14.

Identification of Variants of Hepatitis C Virus (HCV) Entry Factors in Patients Highly Exposed to HCV but Remaining Uninfected: An ANRS Case-Control Study.

Fouquet B, Ghosn J, Quertainmont Y, Salmon D, Rioux C, Duvivier C, Delfraissy JF, Misrahi M.

PLoS One. 2015 Nov 16;10(11):e0142698. doi: 10.1371/journal.pone.0142698. eCollection 2015.

15.

Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro.

Fénéant L, Ghosn J, Fouquet B, Helle F, Belouzard S, Vausselin T, Séron K, Delfraissy JF, Dubuisson J, Misrahi M, Cocquerel L.

PLoS One. 2015 Nov 12;10(11):e0142539. doi: 10.1371/journal.pone.0142539. eCollection 2015.

16.

Drug assessment in the Ebola virus disease epidemic in west Africa.

Yazdanpanah Y, Horby P, van Griensven J, Mentre F, Nguyen VK, Malvy JM, Dunning J, Sissoko D, Delfraissy JF, Levy Y.

Lancet Infect Dis. 2015 Nov;15(11):1258. doi: 10.1016/S1473-3099(15)00344-8. No abstract available.

17.

Residual HIV-1 replication may impact immune recovery in patients on first-line lopinavir/ritonavir monotherapy.

Tran TA, Ghosn J, Avettand-Fenoël V, Hendel-Chavez H, de Goër de Herve MG, Cohen-Codar I, Rouzioux C, Delfraissy JF, Taoufik Y.

J Antimicrob Chemother. 2015 Sep;70(9):2627-31. doi: 10.1093/jac/dkv138. Epub 2015 May 28.

PMID:
26023212
18.

Genome-Wide Association Study of HIV-Related Lipoatrophy in Thai Patients: Association of a DLGAP1 Polymorphism with Fat Loss.

Uttayamakul S, Oudot-Mellakh T, Nakayama EE, Tengtrakulcharoen P, Guergnon J, Delfraissy JF, Khusmith S, Sangsajja C, Likanonsakul S, Theodorou I, Shioda T.

AIDS Res Hum Retroviruses. 2015 Aug;31(8):792-6. doi: 10.1089/AID.2014.0266. Epub 2015 Jun 15.

19.

Efficacy of recombinant human interleukin 7 in a patient with severe lymphopenia-related progressive multifocal leukoencephalopathy.

Gasnault J, de Goër de Herve MG, Michot JM, Hendel-Chavez H, Seta V, Mazet AA, Croughs T, Stankoff B, Bourhis JH, Lambotte O, Delfraissy JF, Taoufik Y.

Open Forum Infect Dis. 2014 Aug 26;1(2):ofu074. doi: 10.1093/ofid/ofu074. eCollection 2014 Sep.

20.

Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial.

Chéret A, Nembot G, Mélard A, Lascoux C, Slama L, Miailhes P, Yeni P, Abel S, Avettand-Fenoel V, Venet A, Chaix ML, Molina JM, Katlama C, Goujard C, Tamalet C, Raffi F, Lafeuillade A, Reynes J, Ravaux I, Hoën B, Delfraissy JF, Meyer L, Rouzioux C; OPTIPRIM ANRS Study Group.

Lancet Infect Dis. 2015 Apr;15(4):387-96. doi: 10.1016/S1473-3099(15)70021-6. Epub 2015 Feb 18.

PMID:
25701561
21.

Towards an HBV cure: state-of-the-art and unresolved questions--report of the ANRS workshop on HBV cure.

Zeisel MB, Lucifora J, Mason WS, Sureau C, Beck J, Levrero M, Kann M, Knolle PA, Benkirane M, Durantel D, Michel ML, Autran B, Cosset FL, Strick-Marchand H, Trépo C, Kao JH, Carrat F, Lacombe K, Schinazi RF, Barré-Sinoussi F, Delfraissy JF, Zoulim F.

Gut. 2015 Aug;64(8):1314-26. doi: 10.1136/gutjnl-2014-308943. Epub 2015 Feb 10. Review.

PMID:
25670809
22.

Claudin-1 gene variants and susceptibility to hepatitis C infection in HIV-1 infected intravenous drug users (an ANRS case-control study).

Ghosn J, Fouquet B, Quertainmont Y, Salmon D, Sahali S, Rioux C, Duvivier C, Mole M, Delfraissy JF, Misrahi M.

J Med Virol. 2015 Apr;87(4):619-24. doi: 10.1002/jmv.24088. Epub 2015 Jan 21.

PMID:
25611191
23.

TB-IRIS, T-cell activation, and remodeling of the T-cell compartment in highly immunosuppressed HIV-infected patients with TB.

Haridas V, Pean P, Jasenosky LD, Madec Y, Laureillard D, Sok T, Sath S, Borand L, Marcy O, Chan S, Tsitsikov E, Delfraissy JF, Blanc FX, Goldfeld AE; CAPRI-T (ANRS 12164) Study Team.

AIDS. 2015 Jan 28;29(3):263-73. doi: 10.1097/QAD.0000000000000546.

24.

CD4+ cell count recovery in naïve patients initiating cART, who achieved and maintained plasma HIV-RNA suppression.

Costagliola D, Lacombe JM, Ghosn J, Delaugerre C, Pialoux G, Cuzin L, Launay O, Ménard A, de Truchis P, Mary-Krause M, Weiss L, Delfraissy JF.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19481. doi: 10.7448/IAS.17.4.19481. eCollection 2014.

25.

Randomised controlled trials for Ebola: practical and ethical issues.

Adebamowo C, Bah-Sow O, Binka F, Bruzzone R, Caplan A, Delfraissy JF, Heymann D, Horby P, Kaleebu P, Tamfum JJ, Olliaro P, Piot P, Tejan-Cole A, Tomori O, Toure A, Torreele E, Whitehead J.

Lancet. 2014 Oct 18;384(9952):1423-4. doi: 10.1016/S0140-6736(14)61734-7. Epub 2014 Oct 13. No abstract available.

26.

Immunohematologic tolerance of chronic transfusion exchanges with erythrocytapheresis in sickle cell disease.

Michot JM, Driss F, Guitton C, Moh Klaren J, Lefebvre F, Chamillard X, Gallon P, Fourn E, Pela AM, Tertian G, Le Bras P, Chantalat-Auger C, Delfraissy JF, Goujard C, Lambotte O.

Transfusion. 2015 Feb;55(2):357-63. doi: 10.1111/trf.12875. Epub 2014 Sep 23.

PMID:
25251746
27.

Virological failure and HIV-1 drug resistance mutations among naive and antiretroviral pre-treated patients entering the ESTHER program of Calmette Hospital in Cambodia.

Barennes H, Guillet S, Limsreng S, Him S, Nouhin J, Hak C, Srun C, Viretto G, Ouk V, Delfraissy JF, Ségéral O.

PLoS One. 2014 Aug 28;9(8):e105736. doi: 10.1371/journal.pone.0105736. eCollection 2014.

28.

Reduction of death receptor 5 expression and apoptosis of CD4+ T cells from HIV controllers.

Barblu L, Smith N, Durand S, Scott-Algara D, Boufassa F, Delfraissy JF, Cimarelli A, Lambotte O, Herbeuval JP.

Clin Immunol. 2014 Nov;155(1):17-26. doi: 10.1016/j.clim.2014.07.010. Epub 2014 Aug 7.

PMID:
25110157
29.

Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.

Raffi F, Babiker AG, Richert L, Molina JM, George EC, Antinori A, Arribas JR, Grarup J, Hudson F, Schwimmer C, Saillard J, Wallet C, Jansson PO, Allavena C, Van Leeuwen R, Delfraissy JF, Vella S, Chêne G, Pozniak A; NEAT001/ANRS143 Study Group.

Lancet. 2014 Nov 29;384(9958):1942-51. doi: 10.1016/S0140-6736(14)61170-3. Epub 2014 Aug 4.

PMID:
25103176
30.

Phenotypic characterization of virological failure following lopinavir/ritonavir monotherapy using full-length Gag-protease genes.

Sutherland KA, Mbisa JL, Ghosn J, Chaix ML, Cohen-Codar I, Hue S, Delfraissy JF, Delaugerre C, Gupta RK.

J Antimicrob Chemother. 2014 Dec;69(12):3340-8. doi: 10.1093/jac/dku296. Epub 2014 Aug 4.

31.

Successful outcome of a corticodependent henoch-schönlein purpura adult with rituximab.

Pindi Sala T, Michot JM, Snanoudj R, Dollat M, Estève E, Marie B, Taoufik Y, Delfraissy JF, Lazure T, Lambotte O.

Case Rep Med. 2014;2014:619218. doi: 10.1155/2014/619218. Epub 2014 Apr 1.

32.

Causes and determinants of mortality in HIV-infected adults with tuberculosis: an analysis from the CAMELIA ANRS 1295-CIPRA KH001 randomized trial.

Marcy O, Laureillard D, Madec Y, Chan S, Mayaud C, Borand L, Prak N, Kim C, Lak KK, Hak C, Dim B, Sok T, Delfraissy JF, Goldfeld AE, Blanc FX; CAMELIA (ANRS 1295-CIPRA KH001) Study Team.

Clin Infect Dis. 2014 Aug 1;59(3):435-45. doi: 10.1093/cid/ciu283. Epub 2014 Apr 23.

33.

Past, present and future: 30 years of HIV research.

Barré-Sinoussi F, Ross AL, Delfraissy JF.

Nat Rev Microbiol. 2013 Dec;11(12):877-83. doi: 10.1038/nrmicro3132. Epub 2013 Oct 28. Review.

PMID:
24162027
34.

Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome after early initiation of antiretroviral therapy in a randomized clinical trial.

Laureillard D, Marcy O, Madec Y, Chea S, Chan S, Borand L, Fernandez M, Prak N, Kim C, Dim B, Nerrienet E, Sok T, Delfraissy JF, Goldfeld AE, Blanc FX; CAMELIA (ANRS 1295 – CIPRA KH001) Study Team.

AIDS. 2013 Oct 23;27(16):2577-86. doi: 10.1097/01.aids.0000432456.14099.c7.

PMID:
24096631
35.

High antibody-dependent cellular cytotoxicity responses are correlated with strong CD8 T cell viral suppressive activity but not with B57 status in HIV-1 elite controllers.

Lambotte O, Pollara J, Boufassa F, Moog C, Venet A, Haynes BF, Delfraissy JF, Saez-Cirion A, Ferrari G.

PLoS One. 2013 Sep 23;8(9):e74855. doi: 10.1371/journal.pone.0074855. eCollection 2013.

36.

Is clinical practice concordant with the changes in guidelines for antiretroviral therapy initiation during primary and chronic HIV-1 infection? The ANRS PRIMO and COPANA cohorts.

Krastinova E, Seng R, Yeni P, Viard JP, Vittecoq D, Lascoux-Combe C, Fourn E, Pahlavan G, Delfraissy JF, Goujard C, Meyer L; ANRS PRIMO and COPANA Cohorts.

PLoS One. 2013 Aug 1;8(8):e71473. doi: 10.1371/journal.pone.0071473. Print 2013. Erratum in: PLoS One. 2013;8(11). doi:10.1371/annotation/aed12a66-9c76-4e49-806b-881a2fe23bba. Goujard, Cecile [added].

37.

Behavioural research in epidemics.

Atlani-Duault L, Rousseau C, Moatti JP, Delfraissy JF, Murgue B.

Lancet Infect Dis. 2013 Jul;13(7):567-8. doi: 10.1016/S1473-3099(13)70097-5. No abstract available.

PMID:
23809219
38.

How evidence based are public health policies for prevention of mother to child transmission of HIV?

Van de Perre P, Tylleskär T, Delfraissy JF, Nagot N.

BMJ. 2013 Jun 20;346:f3763. doi: 10.1136/bmj.f3763. No abstract available.

PMID:
23788455
39.

[HIV: research challenges thirty years after the virus discovery?].

Delfraissy JF.

Med Sci (Paris). 2013 Apr;29(4):339-40. doi: 10.1051/medsci/2013294001. Epub 2013 Apr 26. French. No abstract available.

40.

Risk factors for hepatitis C transmission in HIV patients, Hepacam study, ANRS 12267 Cambodia.

Goyet S, Lerolle N, Fournier-Nicolle I, Ken S, Nouhin J, Sowath L, Barennes H, Hak C, Ung C, Viretto G, Delfraissy JF, Khuon P, Segeral O.

AIDS Behav. 2014 Mar;18(3):495-504. doi: 10.1007/s10461-013-0486-0.

PMID:
23612943
41.

Hope for the eradication of HCV worldwide.

Delfraissy JF.

Liver Int. 2013 Feb;33 Suppl 1:198-9. doi: 10.1111/liv.12077. No abstract available.

PMID:
23286866
42.

Long-term immunogenicity of two doses of 2009 A/H1N1v vaccine with and without AS03(A) adjuvant in HIV-1-infected adults.

Durier C, Desaint C, Lucht F, Girard PM, Lévy Y, May T, Michelet C, Rami A, Roman F, Delfraissy JF, Aboulker JP, Launay O; ANRS 151 study group and the REIVAC network.

AIDS. 2013 Jan 2;27(1):87-93. doi: 10.1097/QAD.0b013e328359f27a.

PMID:
23018437
43.

HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.

Goujard C, Girault I, Rouzioux C, Lécuroux C, Deveau C, Chaix ML, Jacomet C, Talamali A, Delfraissy JF, Venet A, Meyer L, Sinet M; ANRS CO6 PRIMO Study Group.

Antivir Ther. 2012;17(6):1001-9. doi: 10.3851/IMP2273. Epub 2012 Aug 6.

PMID:
22865544
44.

HIV controllers maintain a population of highly efficient Th1 effector cells in contrast to patients treated in the long term.

Vingert B, Benati D, Lambotte O, de Truchis P, Slama L, Jeannin P, Galperin M, Perez-Patrigeon S, Boufassa F, Kwok WW, Lemaître F, Delfraissy JF, Thèze J, Chakrabarti LA.

J Virol. 2012 Oct;86(19):10661-74. doi: 10.1128/JVI.00056-12. Epub 2012 Jul 25.

45.

Plasmacytoid dendritic cells (pDCs) from HIV controllers produce interferon-α and differentiate into functional killer pDCs under HIV activation.

Barblu L, Machmach K, Gras C, Delfraissy JF, Boufassa F, Leal M, Ruiz-Mateos E, Lambotte O, Herbeuval JP; ANRS EP36 HIV Controllers Study Group.

J Infect Dis. 2012 Sep 1;206(5):790-801. Epub 2012 Jun 12.

PMID:
22693234
46.

Multicohort genomewide association study reveals a new signal of protection against HIV-1 acquisition.

Limou S, Delaneau O, van Manen D, An P, Sezgin E, Le Clerc S, Coulonges C, Troyer JL, Veldink JH, van den Berg LH, Spadoni JL, Taing L, Labib T, Montes M, Delfraissy JF, Schachter F, O'Brien SJ, Buchbinder S, van Natta ML, Jabs DA, Froguel P, Schuitemaker H, Winkler CA, Zagury JF.

J Infect Dis. 2012 Apr 1;205(7):1155-62. doi: 10.1093/infdis/jis028. Epub 2012 Feb 23.

47.

Effect of intermittent interleukin-2 therapy on CD4+ T-cell counts following antiretroviral cessation in patients with HIV.

Lévy Y, Thiébaut R, Gougeon ML, Molina JM, Weiss L, Girard PM, Venet A, Morlat P, Poirier B, Lascaux AS, Boucherie C, Sereni D, Rouzioux C, Viard JP, Lane C, Delfraissy JF, Sereti I, Chêne G; ILIADE Study Group.

AIDS. 2012 Mar 27;26(6):711-20. doi: 10.1097/QAD.0b013e3283519214.

PMID:
22301410
48.

[Role of CD4 lymphocytes in the efficient immune response of HIV controllers].

Thèze J, Chakrabarti L, Vingert B, Lambotte O, Delfraissy JF.

Bull Acad Natl Med. 2011 Mar;195(3):545-57; discussion 557-9. French.

PMID:
22292304
49.

Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis.

Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, Madec Y, Marcy O, Chan S, Prak N, Kim C, Lak KK, Hak C, Dim B, Sin CI, Sun S, Guillard B, Sar B, Vong S, Fernandez M, Fox L, Delfraissy JF, Goldfeld AE; CAMELIA (ANRS 1295–CIPRA KH001) Study Team.

N Engl J Med. 2011 Oct 20;365(16):1471-81. doi: 10.1056/NEJMoa1013911.

50.

Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen.

Ghosn J, Delaugerre C, Flandre P, Galimand J, Cohen-Codar I, Raffi F, Delfraissy JF, Rouzioux C, Chaix ML.

PLoS One. 2011;6(9):e24798. doi: 10.1371/journal.pone.0024798. Epub 2011 Sep 20.

Supplemental Content

Loading ...
Support Center